Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium: Comprehensive Analysis Of Synthesis, Properties, And Pharmaceutical Applications

NOV 17, 202671 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium, an internally cross-linked derivative of sodium carboxymethylcellulose, represents a critical pharmaceutical excipient widely employed as a superdisintegrant in solid dosage formulations. This cross-linked polymer exhibits exceptional water-wicking and swelling properties while maintaining structural integrity, enabling rapid tablet disintegration without forming viscous gels. Its fibrous morphology and controlled particle size distribution (typically 90% ≤44.5 µm) contribute to superior performance in oral compacted compositions 3. The material's versatility extends beyond pharmaceutical applications to moisture management in topical formulations and specialized industrial uses 3.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Cross-Linking Chemistry Of Croscarmellose Sodium

Croscarmellose sodium is synthesized through controlled cross-linking of sodium carboxymethylcellulose (NaCMC), a process fundamentally distinct from linear cellulose derivatives. The cross-linking mechanism involves intramolecular esterification achieved by lowering pH during manufacture combined with thermal treatment 3. This structural modification creates a three-dimensional polymer network that prevents dissolution while preserving hydrophilic character.

The optimal degree of substitution (DS) for precursor NaCMC ranges from 0.60 to 0.85 for pharmaceutical-grade croscarmellose sodium production 6. When DS falls within 0.8–0.9, subsequent cross-linking under acidic catalysis (pH 2–4) yields products meeting pharmacopeial standards 6. The cross-linking reaction proceeds in two distinct stages: an initial phase at 40–50°C for 0.5–2.0 hours, followed by a secondary phase at 65–75°C for 2.0–4.0 hours 6. This biphasic thermal profile ensures complete cross-link formation while minimizing polymer degradation.

Recent patent literature describes solvent-mediated synthesis routes employing aqueous organic solvents (water:solvent ratio of 1:10 v/v) with sulfuric acid catalysis (15–30% w/w H₂SO₄) 6. Alternative methodologies utilize hydrochloric acid as both acidifying agent and catalyst in one-pot synthesis, eliminating diethyl ether side reactions and reducing production costs 2. The reaction can be represented schematically as:

NaCMC (DS 0.8-0.9) + H⁺ (catalyst) → Cross-linked NaCMC + H₂O

The fibrous nature of croscarmellose sodium, with particle size predominantly below 44.5 µm, results directly from this cross-linking architecture 3. Unlike non-cross-linked NaCMC which forms pasty gums upon hydration, the cross-linked structure maintains particle integrity during water absorption, a critical attribute for pharmaceutical disintegration applications 3.

Physicochemical Properties And Performance Characteristics

Particle Size Distribution And Morphology

Croscarmellose sodium exhibits well-defined particle size specifications essential for consistent performance. Standard pharmaceutical grades demonstrate 90% of particles ≤44.5 µm 3, though recent innovations have produced fine particle variants with median particle size (D₅₀) ranging from 5 to 36 µm and volume mean diameter (D[4,3]) ≤40 µm 14. These fine particle grades possess specific surface areas ≥0.3 m²/g, with 10th percentile (D₁₀) ≤15 µm and 90th percentile (D₉₀) ≤80 µm 14.

The fibrous morphology distinguishes croscarmellose sodium from other superdisintegrants. This structure facilitates rapid water penetration through capillary action (wicking) while the cross-linked network enables volumetric expansion without structural collapse 3. When exposed to aqueous media, individual particles swell significantly—capable of absorbing multiple times their dry weight in water—yet retain discrete particle identity rather than coalescing into viscous masses 3.

Water Absorption And Swelling Behavior

The water absorption capacity of croscarmellose sodium represents its most functionally significant property. In body powder formulations, concentrations of 2–20% w/w provide enhanced moisture absorbency, with optimal performance observed at 5–20% w/w 3. At these levels, the material can absorb at least 2.5% moisture by weight of the applied composition, with preferred formulations achieving ≥20% moisture absorption based on total composition weight 3.

Critical concentration thresholds exist for different applications. Below approximately 2% w/w, moisture absorbency improvement becomes markedly limited 3. Conversely, concentrations exceeding 20% w/w impart undesirable tactile sensations, as the composition assumes the skin feel of croscarmellose sodium rather than the base powder diluent 3. At levels above 40% w/w, water-swollen particles become visually apparent on moist skin, rendering the product cosmetically unacceptable 3.

Chemical Stability And Compatibility

Croscarmellose sodium demonstrates excellent chemical stability across typical pharmaceutical processing and storage conditions. The cross-linked structure resists hydrolytic degradation that affects linear cellulose ethers. However, formulation scientists must consider potential aging phenomena in certain tablet matrices. Calcium supplement tablets containing compacted tricalcium phosphate, microcrystalline cellulose, and 0.5% croscarmellose sodium exhibited unexpected disintegration time increases after two weeks under stress storage conditions, despite satisfactory initial performance 7.

This aging effect can be mitigated through synergistic excipient combinations. Addition of 50–100% sodium lauryl sulfate (based on croscarmellose sodium weight) minimizes disintegration aging while maintaining acceptable swallowing characteristics 7. The surfactant likely facilitates sustained water penetration by reducing interfacial tension between the hydrophobic tablet matrix and aqueous dissolution media.

Synthesis Routes And Manufacturing Processes For Croscarmellose Sodium

Conventional Aqueous-Organic Solvent Methods

The predominant industrial synthesis employs mixed solvent systems to control cross-linking kinetics and product morphology. A representative process begins with dispersing NaCMC (DS 0.8–0.9) in water:organic solvent mixtures (1:10 v/v ratio) at room temperature, followed by heating to 40–50°C with continuous stirring 6. pH adjustment to 2–4 using sulfuric acid (15–30% w/w) initiates cross-linking, which proceeds through the previously described biphasic thermal profile 6.

Post-reaction workup involves filtration to recover the cross-linked product, followed by sequential washing with water, saturated sodium bicarbonate solution (to neutralize residual acid), additional water rinses, and finally two washes with 60% ethanol 6. The washed filter cake undergoes drying at 70–90°C, mechanical size reduction, and sieving through 200-mesh screens to yield pharmaceutical-grade croscarmellose sodium 6.

This solvent-mediated approach offers several advantages: mild reaction conditions minimize thermal degradation, cross-linking degree remains easily controllable through pH and temperature modulation, and the resulting product meets all Chinese Pharmacopoeia (2010 edition) specifications with quality equivalent to imported materials 16.

One-Pot Hydrochloric Acid Catalysis

An alternative streamlined process utilizes hydrochloric acid as both acidifying agent and catalyst, eliminating organic solvent requirements 2. The procedure involves mixing NaCMC with aqueous ethanol, adding HCl dropwise while controlling temperature (40–50°C), then introducing sodium carbonate solution for continued reaction 2. This one-pot methodology reduces operational steps and avoids diethyl ether formation as a side product 2.

The sole inorganic byproduct, sodium chloride, can be recovered and sold, generating additional revenue streams and further reducing production costs 2. Post-reaction processing follows similar washing protocols: filtration, aqueous rinses, 60% ethanol washes, drying, and milling 2.

Vacuum-Assisted Cross-Linking With Enhanced Purity

A more sophisticated approach addresses impurity introduction during cross-linking 8. This method involves: (1) thermal treatment of NaCMC in water to form a pasty colloid, (2) cooling and mixing with aqueous ethanol to create a suspension, (3) acidification with acetic acid followed by cooling and filtration, (4) multiple washing cycles with ethanol-water solutions to remove reaction byproducts, and (5) vacuum-assisted cross-linking of the purified intermediate 8.

The vacuum environment during cross-linking prevents oxidative side reactions and impurity incorporation, yielding exceptionally pure croscarmellose sodium 8. Acetic acid acidification and subsequent crushing improve polymer fiber fluidity, facilitating downstream processing 8. This method proves particularly suitable for applications requiring stringent purity specifications, such as parenteral or ophthalmic formulations where trace impurities could compromise safety.

Fine Particle Grade Production

Specialized manufacturing techniques produce fine particle croscarmellose sodium with D₅₀ values of 5–36 µm 14. While specific synthesis modifications remain proprietary, achieving these narrow particle size distributions likely involves controlled precipitation conditions, optimized cross-linking kinetics to limit particle aggregation, and advanced milling technologies with classification systems to remove oversized particles. The resulting high specific surface area (≥0.3 m²/g) enhances disintegration kinetics in rapidly dissolving tablet formulations 14.

Pharmaceutical Applications Of Croscarmellose Sodium

Superdisintegrant In Oral Solid Dosage Forms

Croscarmellose sodium functions as a superdisintegrant at concentrations substantially lower than conventional disintegrants, typically 0.5–5% w/w in tablet formulations 3. However, optimal performance often requires 6–16% w/w, particularly for poorly soluble active pharmaceutical ingredients (APIs) 9. In entacapone and nitecapone tablets, croscarmellose sodium concentrations of 8–16% w/w, especially 10–14% w/w, dramatically increase API release rates compared to lower levels 9.

The disintegration mechanism involves three synergistic processes:

  • Wicking: Capillary action draws water into the tablet matrix through the fibrous croscarmellose sodium network
  • Swelling: Absorbed water causes volumetric expansion of individual particles, generating disruptive forces
  • Deformation recovery: The fibrous structure exhibits elastic recovery upon hydration, contributing additional mechanical disruption 3

This multi-modal action distinguishes croscarmellose sodium from other superdisintegrants. Sodium starch glycolate acts primarily through swelling but can form gels at high concentrations, paradoxically increasing disintegration times 14. Crospovidone relies predominantly on swelling without significant wicking 14. Croscarmellose sodium's fibrous morphology enables superior wicking while the cross-linked structure prevents gel formation, providing optimal disintegration across diverse formulation matrices 314.

Taste-Masking Applications Through Particle Coating

Beyond disintegration, croscarmellose sodium serves as an effective taste-masking agent when applied as a coating to bitter APIs 11. Effective taste masking requires 10–50% w/w coating levels (based on substrate weight), preferably 15–28% w/w, most optimally 18–25% w/w 11. At these levels, croscarmellose sodium provides dual functionality: taste masking during oral administration and rapid disintegration post-swallowing 11.

Substrate particle size critically influences taste-masking efficacy. APIs with particle sizes below 60 µm exhibit dramatically reduced taste masking, as do formulations where >1% of particles are <60 µm or >1.5% are <125 µm 11. Optimal substrates possess particle sizes of 50–500 µm in crystalline form rather than powdered form 11. During fluidized bed coating, inlet temperatures must remain below the API melting point to prevent substrate melting, which would compromise coating uniformity 11.

Binders such as ethylcellulose, hydroxypropylmethyl cellulose, methylcellulose, or polyvinylpyrrolidone may be incorporated into coating suspensions to enhance croscarmellose sodium adhesion to API particles 11. This approach proves particularly valuable for pediatric and geriatric formulations where palatability significantly impacts patient compliance.

Formulations With Poorly Compressible Or Water-Unstable APIs

Croscarmellose sodium demonstrates exceptional utility in formulations containing challenging APIs. For water-unstable compounds with hydrolysis-sensitive functional groups (esters, amides, thioesters) or materials exhibiting waxy consistency (glass transition temperature <25°C), croscarmellose sodium provides rapid disintegration that minimizes aqueous exposure time, reducing degradation 10.

In compressed formulations of ordered mesoporous silicas loaded with APIs, croscarmellose sodium (3–20% w/w, preferably 5–15% w/w, optimally 7.5–15% w/w) combines with microcrystalline cellulose (10–90% w/w) to achieve rapid disintegration despite the complex matrix 13. The mesoporous silica enhances API dissolution through amorphous solid dispersion formation, while croscarmellose sodium ensures prompt matrix breakdown to expose the drug-loaded silica particles to dissolution media 13.

Dissolution Enhancement In Tamoxifen Citrate Formulations

Tamoxifen citrate tablets exemplify croscarmellose sodium's dissolution-enhancing capabilities. Formulations containing 5–15% w/w tamoxifen citrate with optimized croscarmellose sodium levels achieve ≥65% drug dissolution within 10 minutes in 1000 mL of 0.02N HCl at 37°C under 100 rpm stirring conditions (USP Apparatus 2) 12. This rapid dissolution profile ensures consistent bioavailability and reduces inter-subject pharmacokinetic variability.

The croscarmellose sodium concentration must be carefully balanced: insufficient levels result in incomplete disintegration and slow dissolution, while excessive amounts may compromise tablet mechanical strength or cause premature disintegration during handling. Formulation development typically involves dissolution testing across a range of croscarmellose sodium concentrations (2–8% w/w) to identify the optimal level for each specific tablet composition and compression force 12.

Analytical Methods For Croscarmellose Sodium Characterization

High-Performance Liquid Chromatography With Charged Aerosol Detection (HPLC-CAD)

Quantitative determination of croscarmellose sodium in pharmaceutical formulations presents analytical challenges due to the polymer's lack of strong chromophores. HPLC-CAD overcomes this limitation through universal detection based on particle charging rather than UV absorption 5. This technique accurately quantifies croscarmellose sodium in complex matrices such as amonavir tablets without interference from other excipients 5.

The method involves preparing reference solutions of known croscarmellose sodium concentration and test solutions from tablet extracts, injecting both into the HPLC-CAD system, and calculating response factors from reference solution peak areas and concentrations 5. Test solution croscarmellose sodium content is then determined from peak areas and the established response factor 5. This approach demonstrates excellent specificity, repeatability, and recovery, with simple sample preparation procedures 5.

Particle Size Analysis

Particle size distribution characterization employs laser diffraction techniques to determine D₁₀, D₅₀, D₉₀, and volume mean diameter (D[4,3]) values 14. These parameters critically influence disintegration performance, flowability, and content uniformity in tablet formulations. Fine particle grades (D₅₀ 5–36 µm) require high-resolution instruments capable of accurately measuring submicron particles, often utilizing wet dispersion methods with appropriate surfactants to prevent agglomeration during measurement 14.

Specific Surface Area Determination

Brunauer-Emmett-Teller (BET) nitrogen adsorption provides specific surface area measurements, with pharmaceutical-grade croscarmellose sodium typically exhibiting values ≥0.3 m²/g 14. Higher specific surface areas correlate with enhanced water absorption kinetics and disintegration rates, making this parameter valuable for quality control and performance prediction.

Moisture Content And Loss On Drying

Karl Fischer titration or thermogravimetric analysis (TGA) quantifies moisture content, an important specification for pharmaceutical excipients. Excessive moisture can promote microbial growth, chemical degradation of moisture-sensitive APIs, and altered flow properties. Pharmacopeial specifications typically limit moisture content to ≤10% w/w for croscarmellose sodium.

Non-Pharmaceutical Applications Of Croscarmellose Sodium

Topical Body Powder Formulations

Croscarmellose sodium's exceptional moisture absorption capacity extends its utility to cosmetic and dermatological applications. Body powder compositions containing 2–20% w/w croscarmellose sodium (preferably 5–20% w/w) with powder diluents such as talc or topical starch provide superior wetness protection and skin irritation prevention compared to conventional formulations 3.

The fibrous cross-linked structure ensures that absorbed moisture does not form pastes

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONRapidly dissolving oral solid dosage forms requiring fast disintegration, particularly for poorly soluble APIs and patient populations requiring quick drug release.Ac-Di-SolFine particle croscarmellose with median particle size 5-36 µm and specific surface area ≥0.3 m²/g provides enhanced disintegration kinetics in rapidly dissolving tablet formulations.
FMC CORPORATIONPediatric and geriatric oral formulations containing bitter-tasting active pharmaceutical ingredients where palatability is critical for patient compliance.Ac-Di-SolCroscarmellose sodium coating at 10-50% w/w (preferably 15-28% w/w) provides effective taste masking while maintaining rapid tablet disintegration through dual functionality as coating and superdisintegrant.
ORION CORPORATIONOral tablet formulations of entacapone and nitecapone for Parkinson's disease treatment requiring enhanced dissolution and bioavailability.Entacapone/Nitecapone TabletsCroscarmellose sodium at 6-16% w/w (optimally 10-14% w/w) dramatically increases API release rates from oral compacted compositions containing catechol derivatives.
COMBE INCORPORATEDTopical body powder applications for moisture management and skin irritation prevention in personal care and dermatological products.Body Powder FormulationCroscarmellose sodium at 2-20% w/w provides enhanced moisture absorbency (≥20% moisture absorption by weight) while maintaining fibrous structure without forming pasty gums.
ELI LILLY AND COMPANYOral solid dosage forms of tamoxifen citrate for breast cancer treatment requiring rapid dissolution to reduce pharmacokinetic variability and ensure therapeutic efficacy.Tamoxifen Citrate TabletsOptimized croscarmellose sodium concentration achieves ≥65% drug dissolution within 10 minutes in 0.02N HCl at 37°C, ensuring rapid dissolution and consistent bioavailability.
Reference
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Preparation method of croscarmellose sodium
    PatentPendingCN118894947A
    View detail
  • Body powder composition
    PatentInactiveUS6143285A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png